Publications by authors named "Jaclyn Neely"

Claim this Profile
N
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial.
Thomas Yau, Peter R Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Jaclyn Neely

Lancet· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial.
Jason J Luke, Katherine Bever, F Stephen Hodi, Janis Taube, Ashish Massey, Jaclyn Neely

J Immunother Cancer· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer.
Mark M Awad, Patrick M Forde, Nicolas Girard, Jonathan Spicer, Changli Wang, Jaclyn Neely

J Clin Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, Tina Cascone, Dirk Schadendorf, Jaclyn Neely

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Julie Stein Deutsch, Ashley Cimino-Mathews, Elizabeth Thompson, Mariano Provencio, Patrick M Forde, Jaclyn Neely

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Jaclyn Neely

J Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification.
Carla Montironi, Florian Castet, Philipp K Haber, Roser Pinyol, Miguel Torres-Martin, Jaclyn Neely

Gut· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatocellular Carcinoma in Mongolia Delineates Unique Molecular Traits and a Mutational Signature Associated with Environmental Agents.
Laura Torrens, Marc Puigvehí, Miguel Torres-Martín, Huan Wang, Miho Maeda, Jaclyn Neely

Clin Cancer Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.
Nicholas Willumsen, Christina Jensen, George Green, Neel I Nissen, Jaclyn Neely

Cell Mol Life Sci· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Jaclyn Neely

Lancet Oncol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.
Masatoshi Kudo, Ana Matilla, Armando Santoro, Ignacio Melero, Antonio Cubillo Gracián, Jaclyn Neely

J Hepatol· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
Bruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S Finn, Ghassan K Abou-Alfa, Jaclyn Neely

J Hepatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Thomas Yau, Yoon-Koo Kang, Tae-You Kim, Anthony B El-Khoueiry, Armando Santoro, Jaclyn Neely

JAMA Oncol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
John Timmerman, Charles Herbaux, Vincent Ribrag, Andrew D Zelenetz, Roch Houot, Jaclyn Neely

Am J Hematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Jaclyn Neely

Lancet· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Neil H Segal, Theodore F Logan, F Stephen Hodi, David McDermott, Ignacio Melero, Jaclyn Neely

Clin Cancer Res· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis